IN THE CLAIMS

Please replace claims 1, 3, 4 and 5 with new claims 1, 3, 4 and 5 as follows, and please cancel claim 9 without prejudice or disclaimer of the subject matter thereof.

IN THE CLAIMS (Clean Sheet)

1. (Twice Amended) A serine protease inhibitor having the formula (I),



in which

J is H, R^1, R^1-O-C(O)-, R^1-C(O)-, R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO-$(CHR^2)_p$-;

W is an amino-acid of the formula -NH-CHR^1-C(O)-, -NR^4-CH($(CH_2)_qC(O)OR^1$)-C(O)-, -NR^4-CH($(CH_2)_qC(O)N(R^{2a},R^{2b})$)-C(O)-, -$NR^4$-CH($(CH_2)_qC(O)$Het)-C(O)-, D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3 Piq, glutanyl or a (C_1-C_6) alkylester thereof;

E is -NR^2-CH_2- or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R^1 is selected form (1-12C)alkyl, (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF_3 or halogen, and from (6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and (14-20C)(bisary)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2, R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which

are unsubstituted or substituted with
(3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen, and from
(6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are
unsubstituted or substituted with
(1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;
R^3 is the same as R^2 or is Het-(1-6C)alkyl;
R^4 is H or (1-3C)alkyl;
X and Y are CH or N, with the proviso that they are not
both N;
Het is a 4-, 5- or 6-membered heterocycle containing
one or more heteroatoms selected from O, N and S;
m is 1 or 2;
p is 1, 2 or 3;
q is 1, 2 or 3;
t is 2, 3 or 4;
or a pharmaceutically acceptable addition salt or
solvate thereof.

3. (Twice Amended) The serine protease inhibitor according to claim 2, wherein

J is H, R^1 R^1-SO_2-, R^3OOC-$(CHR^2)_p$-,
$(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO(CHR^2)p-;

W is an amino-acid of the formula -NH-CHR^1-C(O)-,
-NR^4-CH($(CH_2)_q$C(O)OR^1)-C(O)-,
-NR^4-CH($(CH_2)_q$C(O)N(R^{2a},R^{2b}))-C(O)-,

E is -N(3-6C)cycloalkyl-CH_2- or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl or 1-6C)alkoxy;

R^1 is selected from (1-12C)alkyl, (3-12C)cycloalkyl and

(3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy or oxo, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2 is H;

R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloakyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl;

p is 1;

q is 2;

t is 3 or 4.

4. (Twice Amended) The serine protease inhibitor according to claim 3, wherein

W is an amino-acid of the formula $-NH-CHR^1-C(O)-$ or glutamyl or an (1-6C)alkylester thereof;

R^1 is selected from (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl

or (1-6C)alkoxy, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisary)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy or halogen; and

R^3 is selected from (1-8C)alkyl and (3-8C)cycloalkyl, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl.

5. (Twice Amended) The serine protease inhibitor according to claim 4, wherein

J is $-CH_2COO$(1-6C)alkyl, (3-8C)cycloalkyl, $-SO_2$-10-camphor, $-CH_2CONH$phenyl or $-CH_2CONH$(3-8C)cycloalkyl;

W is D-cyclohexylalaninyl, D-phenylalaninyl, D-diphenylalaninyl or glutamyl, or an (1-6C)alkylester thereof; and

E is the fragment



, wherein t is 3 or 4.